Analyst firms · Barclays · FDMT
Barclays FDMT price target and rating history
4D Molecular Therapeutics Inc. (FDMT) · Health Care
Barclays rates 4D Molecular Therapeutics Inc. (FDMT) Overweight with a $33 price target, as of its latest action on Jan 28, 2026. It has published 3 rating actions on FDMT since April 2024, including 0 upgrades and 0 downgrades. Across 3 firms with a FDMT price target in the last 12 months, the median target is $33. Barclays's target matches it.
- Current rating
- Overweight
- Price target
- $33
- Median target, all firms
- $33
- Actions on FDMT
- 3
Barclays price target on FDMT
Every Barclays rating on FDMT
- Jan 28, 2026
- Apr 15, 2024
- Apr 15, 2024
How other firms rate FDMT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | $20 | Sep 14, 2026 |
| B. Riley Securities | Buy | $37 | Jul 31, 2026 |
| Barclays | Overweight | $33 | Jan 28, 2026 |
Questions about Barclays and FDMT
- What is Barclays's price target for FDMT?
- Barclays's latest stated price target for 4D Molecular Therapeutics Inc. (FDMT) is $33, from its action on Jan 28, 2026.
- What is Barclays's rating on FDMT?
- Barclays rates FDMT Overweight, a bullish rating, as of Jan 28, 2026.
- When did Barclays last change its view on FDMT?
- On Jan 28, 2026, Barclays resumes coverage at Overweight, price target $33.
- How does Barclays's FDMT target compare with other analysts?
- Across 3 firms with a FDMT price target in the last 12 months, the median target is $33. Barclays's target matches it.
More FDMT rating histories
All Barclays ratingsFDMT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.